Development and characterization of PLGA nanospheres and nanocapsules containing xanthone and 3-methoxyxanthone

被引:128
作者
Teixeira, M
Alonso, MJ
Pinto, MMM
Barbosa, CM
机构
[1] CTMUP, Fac Farm Porto, P-4050047 Oporto, Portugal
[2] Univ Porto, Fac Farm, Ctr Estudos Quim Organ Fitoquim & Farmacol, Oporto, Portugal
[3] Inst Super Ciencias Saude Norte, Gandra PRD, Portugal
[4] Fac Farm, Lab Farm Galencia, Santiago De Compostela, Spain
[5] CETMED, Ctr Tecnol Medicamento, Oporto, Portugal
关键词
xanthone; 3-methoxyxanthone; nanoparticles; nanospheres; nanocapsules; PLGA;
D O I
10.1016/j.ejpb.2004.09.002
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The aim of the present work was to develop and characterize two different nanosystems, nanospheres and nanocapsules, containing either xanthone (XAN) or 3-methoxyxanthone (3-MeOXAN), with the final goal of improving the delivery of these poorly water-soluble compounds. The xanthones-loaded nanospheres (nanomatrix systems) and nanocapsules (nanoreservoir systems), made of poly(DL-lactide-co-glycolide) (PLGA), were prepared by the solvent displacement technique. The following characteristics of nanoparticle formulations were determined: particle size and morphology, zeta potential, incorporation efficiency, thermal behaviour, in vitro release profiles and physical stability at 4 degrees C. The nanospheres had a mean diameter < 170 nm, a narrow size distribution (polydispersity index < 0.1), and a negative surface charge (zeta potential < -36 mV). Their incorporation efficiencies were 33% for XAN and 42% for 3-MeOXAN. The presence of the xanthones did not affect the nanospheres size and zeta potential. DSC studies indicated that XAN and 3-MeOXAN were dispersed at a molecular level within the polymeric nanomatrix. Nanocapsules were also nanometric (mean size < 300 nm) and exhibited a negative charge (zeta potential < -36 mV). Their incorporation efficiency values (> 77%) were higher than those corresponding to nanospheres for both xanthones. The release of 3-MeOXAN from nanocapsules was similar to that observed for the correspondent nanoemulsion, indicating that drug release is mainly governed by its partition between the oil core and the external aqueous medium. In contrast, the release of XAN from nanocapsules was significantly slower than from the nanoemulsion, a behaviour that suggests an interaction of the drug with the polymer. Nanocapsule formulations exhibited good physical stability at 4 degrees C during a 4-month period for XAN and during a 3-month period for 3-MeOXAN. (c) 2004 Elsevier B.V. All rights reserved.
引用
收藏
页码:491 / 500
页数:10
相关论文
共 47 条
[1]   Investigation of polymeric nanoparticles as carriers of enalaprilat for oral administration [J].
Ahlin, P ;
Kristl, J ;
Kristl, A ;
Vrecer, F .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2002, 239 (1-2) :113-120
[2]  
Alonso MJ, 1996, DRUGS PHARM SCI, P203
[3]   INVITRO RELEASE KINETIC PATTERN OF INDOMETHACIN FROM POLY(D,L-LACTIDE) NANOCAPSULES [J].
AMMOURY, N ;
FESSI, H ;
DEVISSAGUET, JP ;
PUISIEUX, F ;
BENITA, S .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1990, 79 (09) :763-767
[4]  
[Anonymous], 1992, STP PHARMA SCI
[5]   Encapsulation of hydrophilic and lipophilic drugs in PLGA nanoparticles by the nanoprecipitation method [J].
Barichello, JM ;
Morishita, M ;
Takayama, K ;
Nagai, T .
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 1999, 25 (04) :471-476
[6]  
BARRAT G, 1998, INT J PHARM, V16, P457
[7]   Development and characterization of protein-loaded poly(lactide-co-glycolide) nanospheres [J].
Blanco, MD ;
Alonso, MJ .
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 1997, 43 (03) :287-294
[8]   Comparative in vitro evaluation of several colloidal systems, nanoparticles, nanocapsules, and nanoemulsions, as ocular drug carriers [J].
Calvo, P ;
VilaJato, JL ;
Alonso, MJ .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1996, 85 (05) :530-536
[9]  
CALVO P, 1995, THESIS U SANTIAGO CO, P119
[10]  
COUVREUR P, 1992, J CONTROL RELEASE, V19, P259, DOI 10.1016/0168-3659(92)90081-2